Le Lézard
Classified in: Health, Science and technology
Subject: Stock Sale/Buyback

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the grant of stock options to purchase 120,500 shares of its common stock and the grant of 80,400 restricted stock units (RSUs) to four new employees. The awards were granted pursuant to the Nasdaq inducement grant exception as an inducement material to the employees' acceptance of employment with Verastem Oncology in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price equal to $1.13 per share, the closing price of Verastem Oncology's common stock as reported by Nasdaq on July 1, 2022. The stock options and RSUs that were granted to the four new employees will vest at a rate of twenty-five percent (25%) on the one-year anniversary of the employee's date of hire, with the remaining shares vesting quarterly over the next three (3) years in equal quarterly amounts, provided the employees continue to serve as employees of or other service providers to Verastem Oncology on each such vesting date.

About Verastem Oncology

Verastem Oncology (Nasdaq: VSTM) (Verastem, Inc.) is a development-stage biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition and FAK inhibition. For more information, please visit www.verastem.com.


These press releases may also interest you

at 18:20
Biocom California, the association representing the life science industry of California, issued the following statement regarding the drug pricing portion in the Inflation Reduction Act. The statement can be attributed to Joe Panetta, Biocom...

at 18:05
VIQ Solutions Inc. ("VIQ" or "VIQ Solutions") , a global provider of secure, AI-driven, digital voice and video capture technology and transcription services, today announced its expanded partnership with Law In Order, a leading provider of...

at 17:15
Dr. Neeraj Agarwal will act as a scientific advisor for Vial's Oncology CRO alongside Dr. Guru Sonpavde, Dr. Arati Rao, and Dr. Antoni Ribas. Together, they will lend their expertise to the Vial team as Vial continues to expand their Oncology CRO....

at 17:00
Call Journey joins the growing coalition pledging to advance diversity and inclusion in the workplace. One of over 2,000 CEOs that have come together for CEO Action for Diversity & Inclusiontm, CEO Paul Humphrey is committing himself and Call Journey...

at 04:10
Amgen  today announced three new data sets from its thoracic oncology portfolio that will be presented at the International Association for the Study of Lung Cancer (IASLC) 2022 World...

at 03:20
BiomX Inc. ("BiomX" or the "Company"), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and a live audio...



News published on 7 july 2022 at 07:05 and distributed by: